Actively Recruiting
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-05
133
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Giant cell arteritis (GCA), also known as Horton's disease, is an inflammatory condition affecting large and medium-sized arteries, mainly in people over 50 years old. It can cause serious complications affecting the blood vessels, eyes, nerves, heart, and aorta. Early treatment with corticosteroids is critical to prevent these complications. Traditionally, diagnosis relied on temporal artery biopsy, but current guidelines recommend imaging, especially MRI of the temporal arteries, as a first-line diagnostic tool. This study evaluates the diagnostic performance of several 3D T1 MRI sequences with fat saturation and black blood imaging at different spatial resolutions for detecting GCA. High-resolution MRI sequences (<0.7mm) have shown excellent accuracy but are not widely available. The study aims to see if lower resolution sequences can also provide reliable diagnosis, making advanced MRI techniques more accessible in broader clinical settings. Participants suspected of having GCA will undergo contrast-enhanced 3D T1 MRI scans using various sequences. Researchers will assess inflammation in temporal arteries and related vessels to determine sensitivity for GCA diagnosis. The primary outcome is the sensitivity of MRI inflammation detection at 3 months. Participants will be monitored through imaging results, and safety and diagnostic accuracy will be observed throughout the study, which runs until June 2027.
CONDITIONS
Brief Title
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years of age
- Referred for imaging with injected MRI for suspected giant cell arteritis
- Suspicion of giant cell arteritis based on three major criteria or two major and one minor criteria, including age over 50, recent headache, jaw or tongue claudication, visual problems, or elevated sedimentation rate/CRP
- Consent to participate in the study
- Affiliated or beneficiary of a social security plan
You will not qualify if you...
- Newly diagnosed malignant disease within one year prior to inclusion
- Active infectious disease
- Autoimmune disease such as Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, or periarteritis nodosa
- Systemic corticosteroid therapy over 10 days at high dose (>0.5 mg/kg/day prednisone)
- Contraindication to MRI
- Patient under legal protection measures
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo 3D T1 MRI sequences with fat saturation and black blood to diagnose giant cell arteritis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Hôpital Fondation Adolphe de Rothschild
Paris, France
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here